Latest Articles
NICE Appraisals of Relugolix-CT and Linzagolix for Endometriosis Symptom Management: Commentary on Clinical and Economic Uncertainties.
Published: Feb. 21, 2026, midnight
Potency of oral gonadotropin-releasing hormone antagonist as endometriosis-associated pain novel treatments: An updated meta-analysis of randomized controlled trials.
Elagolix, Linzagolix, and Relugolix, as oral gonadotropin-releasing hormone antagonists, have emerged as promising treatments for endometriosis-associated pain.
Published: Nov. 1, 2025, midnight
Linzagolix - new perspectives in the pharmacotherapeutic management of uterine fibroids and endometriosis.
Uterine fibroids and endometriosis are among the most common conditions encountered in gynaecological practice. Fibroids affect 30-70% of women, with up to half experiencing symptoms that significantly impair quality of …
Published: July 28, 2025, midnight
Link copied to clipboard!